


CLAIMS

1. A compound of general formula I:



5 wherein m is an integer from 1 to 2;

R_1^a , R_1^b , R_1^c , R_1^d , R_1^e , and R_1^f , each independently represents hydrogen, C_1 - C_6 alkyl; $-NH_2$, $-NHC_1$ - C_6 alkyl, hydroxyl, or C_1 - C_6 alkoxy;

R_2 is hydrogen, C_1 - C_6 alkyl, $-C(O)OH$, $-C(O)OC_1$ - C_6 alkyl;

10 R_3 is:

1) a 5-membered saturated or unsaturated heterocyclic group comprising from 1 to 4 heteroatoms selected from N, O and S, optionally substituted with 1 to 3 substituents selected from halogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $-C(O)OH$, $-C(O)OC_1$ - C_6 alkyl, $-NHC(O)C_1$ - C_6 alkyl, phenyl, or pyridinyl;

2) a 6-membered saturated or unsaturated heterocyclic group comprising from 1 to 2 heteroatoms selected from N and O, optionally substituted with a group selected from halogen and C_1 - C_6 alkyl;

20 3) a 5-membered unsaturated heterocyclic group comprising from 1 to 3 heteroatoms selected from N and S, optionally substituted with 1 or 2 substituents selected from C_1 - C_6 alkyl, condensed with a 6-membered unsaturated nitrogen-containing cyclic or heterocyclic group optionally substituted with 1 or 2 substituents selected from hydroxyl, halogen or C_1 - C_6 alkyl;


4) a 6-membered unsaturated cyclic or heterocyclic group comprising from 1 to 2 nitrogen atoms, condensed with a 5- or 6-membered unsaturated heterocyclic group comprising from 1 to 3 heteroatoms selected from N and S;
 5 or

5) a group of the formula:




or a pharmaceutically acceptable salt thereof,
 with a proviso that the compound is not a compound,
 10 wherein:


when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is $-C(O)OCH_3$, R_3 is not:




when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen
 15 and R_2 is hydrogen, R_3 is not:




when m is 1, R^a_1 is an amino group and R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen, or R^e_1 is an amino group and R^a_1 , R^b_1 , R^c_1 , R^d_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is
 20 not:



when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is not:




5 when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is not:




when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is not:



10 when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is not:




when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is not:




15


when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is not:



when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is $-C(O)OH$, R_3 is not:



5 when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is $-C(O)OH$, R_3 is not:



when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is not:



10


when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is not:




15 when m is 2, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is not:








when m is 2, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is not:












when m is 1, R^a_1 , R^b_1 , R^c_1 , R^d_1 , R^e_1 , and R^f_1 are hydrogen and R_2 is hydrogen, R_3 is not:




5 and with a proviso that the compound is not the following compound:







and



5

2. The compound of claim 1, wherein

R^a_1 and R^b_1 are hydrogen, methyl, amino, or hydroxyl;










R^c_1 and R^d_1 are hydrogen, methyl, amino, or hydroxyl;




























R^e_1 and R^f_1 are hydrogen or methyl;




























10 R_2 is hydrogen, methyl, carboxyl, methoxycarbonyl, or ethoxycarbonyl;






















R_3 is




a group selected from:






























, and



























or a pharmaceutically acceptable salt thereof.













3. The compound of claim 1, which is:










































































, or



4. A medicament for the treatment of a respiratory tract disease, which is a compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

5. The medicament of claim 4, wherein the respiratory tract disease is rhinosinusitis.

6. The medicament of claim 4, wherein the respiratory tract disease is caused by an RNA-comprising virus.

7. The medicament of claim 6, wherein the virus is selected from the group consisting of rhinovirus, Coxsackie virus, respiratory syncytial virus, and influenza virus.

10

8. The medicament of claim 4, wherein the disease is exacerbations of asthma, chronic obstructive pulmonary disease, bronchitis and mucoviscidosis, which are caused by rhinovirus, influenza virus and/or respiratory syncytial virus.

15

9. A pharmaceutical composition for the treatment of a respiratory tract disease, comprising an effective amount of a compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20

10. The pharmaceutical composition of claim 9, wherein the respiratory tract disease is rhinosinusitis.

25

11. The pharmaceutical composition of claim 9, wherein the respiratory tract disease is caused by an RNA-comprising virus.

30

12. The pharmaceutical composition of claim 11, wherein the virus is selected from the group consisting of rhinovirus, Coxsackie virus, respiratory syncytial virus, and influenza.

13. The pharmaceutical composition of claim 9, wherein the
disease is exacerbations of asthma, chronic obstructive
pulmonary disease, bronchitis and mucoviscidosis, which are
5 caused by rhinovirus, influenza virus and/or respiratory
syncytial virus.